| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Research Abstract |
In postmenopausal breast cancers, CAFs(carcinoma-associated fibroblasts) express aromatase, and locally produce estrogen to activate the estrogen receptor(ER). We established a reporter cell system to detect the ER-activating ability of CAFs under coculture with MCF-7-E10 cells stably transfected with the ERE-GFP gene, and ER activity in breast cancer cells in primary culture by adenovirus-mediated introduction of the ERE-GFP reporter gene. In the cases in which ER-activating abilities of CAF were low, ER-activating abilities correlated with aromatase expression. In these cases, neoadjuvant hormonal therapy with an aromatase inhibitor, exemestane, decreased ER activities in tumor cells and led to a favorable clinical response. Functional analysis of CAF for individual breast cancers might be important to predict the endocrine therapy.
|
